Healthcare provider profile · identity verified

Sara August, MD

Family Practice · COTTAGE GROVE, MN · NPI 1952364903

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	192	56
Levothyroxine Sodium	Levothyroxine Sodium	190	46
Omeprazole	Omeprazole	136	38
Losartan Potassium	Losartan Potassium	131	39
Amlodipine Besylate	Amlodipine Besylate	103	28
Lisinopril	Lisinopril	98	33
Rosuvastatin Calcium	Rosuvastatin Calcium	92	32
Tramadol Hcl	Tramadol Hcl	86	18
Metoprolol Succinate	Metoprolol Succinate	79	22
Hydrochlorothiazide	Hydrochlorothiazide	78	25
Gabapentin	Gabapentin	76	20
Bupropion Xl	Bupropion Hcl	65	17
Trazodone Hcl	Trazodone Hcl	63	20
Simvastatin	Simvastatin	57	19
Venlafaxine Hcl Er	Venlafaxine Hcl	57	suppressed
Famotidine	Famotidine	54	suppressed
Sertraline Hcl	Sertraline Hcl	54	14
Alendronate Sodium	Alendronate Sodium	48	18
Albuterol Sulfate Hfa	Albuterol Sulfate	44	26
Pantoprazole Sodium	Pantoprazole Sodium	40	14
Tizanidine Hcl	Tizanidine Hcl	39	11
Fluoxetine Hcl	Fluoxetine Hcl	34	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	33	suppressed
Metformin Hcl	Metformin Hcl	33	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	32	suppressed
Eliquis	Apixaban	30	suppressed
Duloxetine Hcl	Duloxetine Hcl	29	suppressed
Potassium Chloride	Potassium Chloride	29	suppressed
Fenofibrate	Fenofibrate,micronized	28	suppressed
Furosemide	Furosemide	28	11
Topiramate	Topiramate	28	suppressed
Metformin Hcl Er	Metformin Hcl	27	suppressed
Atenolol	Atenolol	26	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	26	suppressed
Mirtazapine	Mirtazapine	26	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	24	suppressed
Ozempic	Semaglutide	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Chlorthalidone	Chlorthalidone	22	suppressed
Pravastatin Sodium	Pravastatin Sodium	22	suppressed
Temazepam	Temazepam	22	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Warfarin Sodium	Warfarin Sodium	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	19	suppressed
Prednisone	Prednisone	19	11
Valacyclovir	Valacyclovir Hcl	19	suppressed
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	18	18
Sumatriptan Succinate	Sumatriptan Succinate	17	suppressed
Allopurinol	Allopurinol	16	suppressed
Clobetasol Propionate	Clobetasol Propionate	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Propranolol Hcl Er	Propranolol Hcl	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	15	15
Cephalexin	Cephalexin	15	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Carvedilol	Carvedilol	14	suppressed
Glipizide Er	Glipizide	14	suppressed
Risperidone	Risperidone	14	suppressed
Tacrolimus	Tacrolimus	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Donepezil Hcl	Donepezil Hcl	13	suppressed
Fluticasone Propionate	Fluticasone Propionate	13	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	13	suppressed
Glipizide	Glipizide	12	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	11	11
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Montelukast Sodium	Montelukast Sodium	11	suppressed
Nystatin	Nystatin	11	suppressed
Spironolactone	Spironolactone	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error